Ginkgo Bioworks Holdings, Inc. (DNA) financial statements and ratios from SEC XBRL: revenue $170.16M (TTM), net margin -183.8%, revenue growth -59.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $170.16M |
| Net Margin | -183.8% |
| Revenue Growth (YoY) | -59.7% |
| EPS Growth (YoY) | -17.3% |
| FCF Growth (YoY) | -17.8% |
| Price / Book | 1.03 |
| Price / Sales | 3.23 |
| FCF Yield | -36.9% |
| Altman Z-Score | -7.64 (distress) |
| Sector P/E (Healthcare) | 21.7 |
DNA overview · DNA earnings · DNA KPIs · DNA investor relations · DNA ownership · DNA peers · DNA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.